"This is a very exciting year for Alligator. We currently
have two projects – ADC-1013 and ATOR-1015 – in clinical
development. These projects will soon be joined by ATOR-1017," CEO
Per Norlén comments.
Read the complete report in the pdf below.
The information was submitted for publication at 8:00 a.m.
CEST on April 17, 2019.
For further information, please contact:
Per Norlén
CEO
per.norlen@alligatorbioscience.com
046-540-82-00
Per-Olof Schrewelius
CFO
per-olof.schrewelius@alligatorbioscience.com
046-540-82-03
Cecilia Hofvander
Director IR & Communications
cecilia.hofvander@alligatorbioscience.com
046-540-82-06
Alligator Bioscience AB (publ) 556597-8201
Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden
Phone +46-46-540-82-00
www.alligatorbioscience.com
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's growing pipeline includes five lead clinical and
preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017,
ALG.APV-527 and ATOR-1144. Alligator's shares are listed on Nasdaq
Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55
employees. For more information, please visit
www.alligatorbioscience.com.
ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for
global development and commercialization.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-ab--publ--interim-report-january-march-2019,c2789720
The following files are available for download:
https://mb.cision.com/Main/12681/2789720/1027439.pdf
|
Alligator Bioscience
AB (publ) Interim report January-March 2019
|
View original
content:http://www.prnewswire.com/news-releases/alligator-bioscience-ab-publ-interim-report-january-march-2019-300833596.html
SOURCE Alligator Bioscience